{"log_id": 4023481160633138135, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 1.7e-05, "average": 0.997209, "min": 0.984149}, "location": {"width": 435, "top": 139, "height": 32, "left": 189}, "words": "补充申请:按局24号令修改说明书、标签"}, {"probability": {"variance": 0, "average": 0.999459, "min": 0.998582}, "location": {"width": 197, "top": 133, "height": 46, "left": 895}, "words": "资料编号:3"}, {"probability": {"variance": 0.000185, "average": 0.994037, "min": 0.942677}, "location": {"width": 873, "top": 199, "height": 42, "left": 232}, "words": "为评价克拉霉素的致突变能力,进行了非活性和大鼠肝微粒体活性实验系统(Ames实"}, {"probability": {"variance": 0.012421, "average": 0.97288, "min": 0.379279}, "location": {"width": 910, "top": 247, "height": 43, "left": 188}, "words": "验)。结果表明,药物浓度为每碟25g或更低时,无致突变能力。浓度为50μg时,对"}, {"probability": {"variance": 6e-06, "average": 0.997043, "min": 0.990837}, "location": {"width": 230, "top": 298, "height": 30, "left": 189}, "words": "所有实验菌株产生毒性"}, {"probability": {"variance": 5.6e-05, "average": 0.995834, "min": 0.977697}, "location": {"width": 153, "top": 393, "height": 30, "left": 191}, "words": "【药代动力学】"}, {"probability": {"variance": 0.000114, "average": 0.995613, "min": 0.939536}, "location": {"width": 864, "top": 440, "height": 41, "left": 230}, "words": "成人口服克拉霉素后的药物动力学研究结果表明,克拉霉素口服吸收快,绝对生物利"}, {"probability": {"variance": 3.3e-05, "average": 0.996418, "min": 0.972812}, "location": {"width": 900, "top": 488, "height": 41, "left": 182}, "words": "用度为约50%。多剂量无蓄积,且代谢方式不变。进食能增加生物利用度约25%,但这种"}, {"probability": {"variance": 9e-06, "average": 0.998461, "min": 0.982872}, "location": {"width": 726, "top": 536, "height": 38, "left": 183}, "words": "增加对在推荐剂量范围内无临床意义。食物对克拉霉素的药动学无影响"}, {"probability": {"variance": 0, "average": 0.999944, "min": 0.999941}, "location": {"width": 48, "top": 586, "height": 27, "left": 186}, "words": "体外"}, {"probability": {"variance": 0.00267, "average": 0.98468, "min": 0.721992}, "location": {"width": 853, "top": 631, "height": 43, "left": 227}, "words": "体外研究表明,浓度为0.45~4.5μg/ml时,克拉霉素的人血浆蛋白平均结合率约"}, {"probability": {"variance": 0.001503, "average": 0.984392, "min": 0.775764}, "location": {"width": 899, "top": 677, "height": 46, "left": 181}, "words": "为70%;浓度为45μg/ml时,结合率下降为41%,提示结合位点饱和,但该浓度远远高"}, {"probability": {"variance": 0, "average": 0.998829, "min": 0.997708}, "location": {"width": 165, "top": 727, "height": 30, "left": 180}, "words": "于药物治疗浓度"}, {"probability": {"variance": 0, "average": 0.999693, "min": 0.999436}, "location": {"width": 50, "top": 777, "height": 28, "left": 181}, "words": "体内"}, {"probability": {"variance": 1.2e-05, "average": 0.997648, "min": 0.984015}, "location": {"width": 844, "top": 823, "height": 44, "left": 223}, "words": "动物实验结果表明,除中枢系统外,组织中克拉霉素浓度较循环系统中高数倍。通"}, {"probability": {"variance": 1.5e-05, "average": 0.997294, "min": 0.986596}, "location": {"width": 629, "top": 874, "height": 32, "left": 177}, "words": "常,肝、肺中药物浓度最高,其组织与血浆浓度比为10至20"}, {"probability": {"variance": 0, "average": 0.999345, "min": 0.998477}, "location": {"width": 120, "top": 920, "height": 29, "left": 179}, "words": "健康受试者"}, {"probability": {"variance": 0.002971, "average": 0.982194, "min": 0.698071}, "location": {"width": 857, "top": 966, "height": 42, "left": 224}, "words": "克拉霉素250mg,日服两次,2-3天可达稳态峰值血药浓度,克拉霉素和14-0H克拉"}, {"probability": {"variance": 0.002218, "average": 0.981789, "min": 0.770905}, "location": {"width": 834, "top": 1013, "height": 43, "left": 176}, "words": "霉素的稳态峰值浓度Cmax分别为1和0.6μg/ml,半衰期分别为3-4和5-6小时"}, {"probability": {"variance": 0.00626, "average": 0.978508, "min": 0.499479}, "location": {"width": 829, "top": 1062, "height": 43, "left": 222}, "words": "500mg,日服两次,克拉霉素及其14-OH代谢物在第5剂时可达稳态峰值血药浓度"}, {"probability": {"variance": 0.001757, "average": 0.98481, "min": 0.74579}, "location": {"width": 904, "top": 1108, "height": 45, "left": 175}, "words": "第5和第7剂后,克拉霉素的稳态峰值浓度Cmax分别为27和2.9μg/ml,14-0H克拉"}, {"probability": {"variance": 0.008932, "average": 0.964649, "min": 0.528432}, "location": {"width": 883, "top": 1155, "height": 45, "left": 176}, "words": "霉素的稳态峰值浓度Cmax分别为0.88和0.83μg/ml。半衰期分别为4.5-4.8和6.9"}, {"probability": {"variance": 0.000127, "average": 0.992452, "min": 0.970413}, "location": {"width": 93, "top": 1206, "height": 27, "left": 171}, "words": "8.7小时"}, {"probability": {"variance": 0.003633, "average": 0.974077, "min": 0.731982}, "location": {"width": 866, "top": 1251, "height": 44, "left": 220}, "words": "稳态时,14-0H克拉霉素浓度不随克拉霉素剂量成比例增加。克拉霉素及其14-OH代"}, {"probability": {"variance": 0.023927, "average": 0.943569, "min": 0.392041}, "location": {"width": 906, "top": 1295, "height": 53, "left": 173}, "words": "谢物的半衰期在高剂量时延长。高剂量时,克拉霉素的非线性药物动力学行典心"}, {"probability": {"variance": 0.007842, "average": 0.965463, "min": 0.630345}, "location": {"width": 735, "top": 1345, "height": 45, "left": 173}, "words": "和N脱甲基产物的减少预示着克拉霉素的非战性代谢在高浓度时变得更"}, {"probability": {"variance": 0.05122, "average": 0.773449, "min": 0.54713}, "location": {"width": 126, "top": 1325, "height": 67, "left": 934}, "words": "制药"}, {"probability": {"variance": 0.018843, "average": 0.931771, "min": 0.353317}, "location": {"width": 752, "top": 1392, "height": 50, "left": 220}, "words": "成人口服单剂量克拉霉素250或120时,肾持泄分别为37.9"}, {"probability": {"variance": 0.001064, "average": 0.984529, "min": 0.859506}, "location": {"width": 581, "top": 1444, "height": 40, "left": 173}, "words": "分别为40.2%和29.1%(包括一个14.1%的受试者的数据)"}, {"probability": {"variance": 1e-05, "average": 0.996762, "min": 0.993676}, "location": {"width": 48, "top": 1496, "height": 25, "left": 176}, "words": "患者"}, {"probability": {"variance": 0.00389, "average": 0.983997, "min": 0.62006}, "location": {"width": 864, "top": 1542, "height": 44, "left": 219}, "words": "克拉霉素及其14-0H代谢物极易在组织和体液中分布。少数病例的数据提示,口服克"}, {"probability": {"variance": 0.001648, "average": 0.989648, "min": 0.743463}, "location": {"width": 910, "top": 1589, "height": 46, "left": 171}, "words": "拉霉素后,脑脊液中的药物浓度不能达到有效血药浓度,即由于血脑屏障,脑脊液中的药"}], "language": 3}